Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | TK1 | P04183 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.34 |
| ▸ | PNP | P00491 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Famciclovir SCHEMBL15228828 | 0.95 | ALDH1A1 (0.65) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL20570567 | 0.86 | MEN1 (0.59) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| Valganciclovir SCHEMBL17219665 | 0.86 | ALDH1A1 (0.57) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL18526964 | 0.85 | MEN1 (0.58) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| Monoacetyl-6-Deoxy Penciclovir SCHEMBL1878763 | 0.84 | KDM4E (0.89) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL29357294 | 0.83 | KDM4E (1.00) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL8190642 | 0.83 | KDM4E (1.00) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL2949 | 0.83 | KDM4E (1.00) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL6471750 | 0.82 | KDM4E (0.94) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 | |
| Famciclovir SCHEMBL6471652 | 0.82 | KDM4E (0.98) | ALDH1A1KDM4EHPGDADRA1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221061-A1 | Lung-Targeted Drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-11 | — | — | US | claimed |
| EP-1831235-A2 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006066074-A2 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-06-22 | — | — | WO | claimed |
| US-8871735-B2 | Methods and compositions for providing cardiac protection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130131005-A1 | METHODS AND COMPOSITIONS FOR PROVIDING CARDIAC PROTECTION | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2013-05-23 | — | — | US | disclosed |
| US-8318700-B2 | Lung-targeted drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120122818-A1 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-17 | — | — | US | disclosed |
| US-8101745-B2 | Conjugate cidofovir, idoxuridine, vidarabine, trifluridine, acyclovir, famciclovir penciclovir, valacyclovir, ganciclovir, antiviral, antimicrobial, cancer drug of interest to glycerol ethers or glycerol phosphate ethers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110021453-A1 | Methods and compositions for providing cardiac protection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2011-01-27 | — | — | US | disclosed |
| EP-1824482-A4 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009099676-A1 | TYPE 5 ADENYLYL CYCLASE INHIBITORS FOR PROVIDING CARDIAC PROTECTION | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2009-08-13 | — | — | WO | disclosed |
| EP-2034834-A2 | PRODRUGS OF 5-AMINO-3-(3'-DEOXY-BETA -D-RIBOFURANOSYL)-THIAZOLO[4,5-d]PYRIMIDIN-2,7-DIONE | Anadys Pharmaceuticals, Inc. (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20080221061-A1 | Lung-Targeted Drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2007150002-A2 | PRODRUGS OF 5-AMINO-3-(3'-DEOXY-β-D-RIBOFURANOSYL)-THIAZOLO[4,5-d] PYRIMIDIN-2,7-DIONE | ANADYS PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| EP-1831235-A2 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1824482-A1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | Anadys Pharmaceuticals, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006066074-A2 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006066080-A1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221061-A1 | Lung-Targeted Drugs | DGKG, GK, PHOSPHO1 | ALDH1A1 4007/4885KDM4E 1694/4885HPGD 1715/4885 |
| US-20120122818-A1 | LUNG-TARGETED DRUGS | DGKG, GK, PHOSPHO1 | ALDH1A1 4007/4885KDM4E 1694/4885HPGD 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.